Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 12;64(40):7632-7639.
doi: 10.1021/acs.jafc.6b02723. Epub 2016 Sep 27.

Urinary Excretion of the β-Adrenergic Feed Additives Ractopamine and Zilpaterol in Breast and Lung Cancer Patients

Ting-Yuan David Cheng  1 , Weilin L Shelver  2 , Chi-Chen Hong  1 , Susan E McCann  1 , Warren Davis  1 , Yali Zhang  1 , Christine B Ambrosone  1 , David J Smith  2
Affiliations

Urinary Excretion of the β-Adrenergic Feed Additives Ractopamine and Zilpaterol in Breast and Lung Cancer Patients

Ting-Yuan David Cheng et al. J Agric Food Chem. .

Abstract

β2-Adrenergic agonists (β-agonists) have been legally used in the U.S. for almost two decades to increase lean muscle mass in meat animals. Despite a cardiotoxic effect after high-dose exposure, there has been limited research on human β-agonist exposures related to meat consumption. We quantified urinary concentrations of ractopamine and zilpaterol, two FDA-approved β-agonist feed additives, and examined the extent to which the concentrations were associated with estimated usual meat intake levels. Overnight urine samples from 324 newly diagnosed breast cancer patients and spot urine samples from 46 lung cancer patients at the time of diagnosis, prior to treatment, were collected during 2006-2010 and 2014-2015, respectively. Urinary ractopamine and zilpaterol concentrations were measured by LC-MS/MS. Ractopamine and zilpaterol, respectively, were detected in 8.1% and 3.0% of the urine samples collected (n = 370). Only 1.1% (n = 4) of the urine samples had zilpaterol concentrations above the limit of quantification, with the mean value of 0.07 ng/mL in urine. The presence of detectable ractopamine and zilpaterol levels were not associated with meat consumption estimated from a food frequency questionnaire, including total meat (P = 0.13 and 0.74, respectively), total red meat (P = 0.72 and 0.74), unprocessed red meat (P = 0.74 and 0.73), processed red meat (P = 0.72 and 0.15), and poultry intake (P = 0.67 for ractopamine). Our data suggest that the amount of meat-related exposure of β-agonists was low.

Keywords: cancer; meat consumption; ractopamine; urine; zilpaterol; β2-adrenergic agonists.

PubMed Disclaimer

Conflict of interest statement

Declaration: There are no competing financial interests for all authors.

Figures

Figure 1
Figure 1
Chemical structures of ractopamine and zilpaterol
Figure 2
Figure 2
MS/MS mass chromatograms for ractopamine and zilpaterol. Panel A represents 1 ng/mL of ractopamine and zilpaterol in 20% acetonitril/0.1% formic acid; Panel B represents final concentration of 1ng/mL of ractopamine and zilpaterol from urine extract (original urine concentration 0.1 ng/mL).
Figure 2
Figure 2
MS/MS mass chromatograms for ractopamine and zilpaterol. Panel A represents 1 ng/mL of ractopamine and zilpaterol in 20% acetonitril/0.1% formic acid; Panel B represents final concentration of 1ng/mL of ractopamine and zilpaterol from urine extract (original urine concentration 0.1 ng/mL).
See this image and copyright information in PMC

References

    1. USDA Food Safety and Inspection Service. United States National Residue Program for Meat, Poultry, and Egg Products. 2013 Residue Sample Results. 2015
    1. USDA Food Safety and Inspection Service. United States National Residue Program for Meat, Poultry, and Egg Products. 2014 Residue Sample Results. 2015
    1. Baynes RE, Dedonder K, Kissell L, Mzyk D, Marmulak T, Smith G, et al. Health concerns and management of select veterinary drug residues. Food Chem Toxicol. 2016;88:112–22. - PubMed
    1. Mason S. Tissue residues and withdrawal times. In: Riviere JE, editor. Comparative Pharmacokinetics, Principles, Techniques & Applications. 2. West Sussex, UK: Wiley Blackwell; 2011. pp. 413–23.
    1. Kuiper HA, Noordam MY, van Dooren-Flipsen MM, Schilt R, Roos AH. Illegal use of beta-adrenergic agonists: European Community. J Anim Sci. 1998;76:195–207. - PubMed